PhD Enquiry: Non-Viral Gene Delivery
School of Pharmacy
- Location
- Belfast, United Kingdom
- Funding
- See university guidance
- Application deadline
- See university guidance
About the project
Dr McErlean’s research focuses on innovative gene delivery technologies based on cell-penetrating peptides. Her work aims to overcome biological barriers to enable targeted delivery of nucleic acids for the treatment of neurological, retinal and other chronic diseases, as well as for the engineering of immune cells for adoptive cell therapies. Research within the group combines expertise in nanomedicine, drug delivery, biotechnology and pharmaceutical sciences, providing multidisciplinary training for students interested in the translation of innovative gene and cell therapy technologies.
- Dr Emma McErlean: School of Pharmacy
Contact info
- View Academic Profile
- E.McErlean@qub.ac.uk
Research Interests
Open to PhD applications in the fields of non-viral gene delivery, nanomedicine, biopharmaceutics, nucleic acid therapeutics and advanced cell therapies.
Make a PhD enquiry
- Development of targeted nanomedicines for neurological, retinal and other chronic diseases
- Design and optimisation of non-viral gene delivery systems based on novel cell-penetrating peptides
- Delivery of nucleic acid therapeutics, including mRNA, siRNA, antisense oligonucleotides (ASOs) and gene-editing cargoes
- Engineering immune cells for adoptive cell therapies through advanced nucleic acid delivery approaches
- Overcoming biological barriers for tissue-targeted and mucosal drug and gene delivery
- Translation of innovative drug and gene delivery technologies towards clinical application
Public outreach & key achievements
Dr McErlean is committed to ensuring that research in advanced therapeutics delivers meaningful benefits for patients and society. Alongside her research programme in non-viral gene delivery and nanomedicine, she actively engages with patients, charities, healthcare professionals, policymakers and industry partners to help shape future research priorities and accelerate the translation of innovative therapies.
Her activities span public outreach, patient and public involvement (PPI), professional leadership and research commercialisation, providing opportunities for students to develop skills beyond the laboratory and gain experience at the interface of science, healthcare and policy.
Selected activities and achievements:
- Executive Board Member, Irish Society for Gene and Cell Therapy (ISGCT).
- School of Pharmacy Lead for Outreach and Recruitment, Queen's University Belfast.
- Organiser and contributor to public engagement initiatives including the Northern Ireland Science Festival and Science at Queen's.
- Active involvement in Patient and Public Involvement (PPI) activities with organisations including Prostate Cancer UK and the Lewy Body Dementia Research Advisory Group.
- Contributor to stakeholder engagement events with charities including Leukaemia & Lymphoma NI, working alongside patients, healthcare professionals, researchers and policymakers, to discuss priorities in health research and innovation.
- Collaborative research partnerships spanning academia, healthcare and industry to support the development and translation of next-generation gene and cell therapies.
Research students
PhD Title | Novel peptide delivery technologies for targeted nucleic acid delivery and immune cell engineering in glioblastoma
Name | Ciaran McGranaghan
Years of Study | 2024 - 2027
Country | Northern Ireland
PhD Title | Next-generation peptide delivery platforms for targeted nucleic acid delivery in colorectal cancer
Name | Zixu Liu
Years of Study | 2025 - 2028
Country | China
PhD Title | In vivo CAR-T engineering using targeted peptide delivery systems for treatment of acute lymphoblastic leukaemia (ALL)
Name | Darren Gilhawley
Years of Study | 2026 - 2029
Country | Republic of Ireland
Discover More
Please see my Google Scholar profile for a curated list of recent publications.
Selected Publications:
McErlean et al. https://link.springer.com/article/10.1186/s12951-024-02746-4
McErlean et al. 1016/j.jconrel.2020.11.037
McErlean et al. https://doi.org/10.1016/j.ijpharm.2021.120223